<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02754193</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A00377-44</org_study_id>
    <nct_id>NCT02754193</nct_id>
  </id_info>
  <brief_title>Effects of Induced Moderate HYPOthermia on Mortality in Cardiogenic Shock Patients Rescued by Veno-arterial ExtraCorporeal Membrane Oxygenation (ECMO)</brief_title>
  <acronym>HYPO-ECMO</acronym>
  <official_title>Effects of Induced Moderate HYPOthermia on Mortality in Cardiogenic Shock Patients Rescued by Veno-arterial ExtraCorporeal Membrane Oxygenation (ECMO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, prospective, controlled, randomized (moderate hypothermia 33°C≤ T°C ≤34°C)
      during 24 hours ± 1h versus normothermia (36°C≤ T°C ≤37°C), comparative open trial will be
      conducted on two parallel groups of patients with cardiogenic shock treated with VA-ECMO.

      The HYPO-ECMO trial will test the hypothesis that moderate hypothermia (temperature between
      33°C≤ T°C ≤34°C) associated with VA-ECMO support results in a reduction in 30-day mortality
      in comparison with the normothermia group (36°C≤ T°C ≤37°C).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 10, 2016</start_date>
  <completion_date type="Anticipated">January 14, 2020</completion_date>
  <primary_completion_date type="Actual">July 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>Day 30</time_frame>
    <description>The study objective is to determine whether early moderate hypothermia (33°C≤ T°C ≤34°C) is superior to normothermia (37°C ± 0.3°C) in patients with cardiogenic shock treated with VA-ECMO with respect to 30-day mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Hour 48, Day 7, Day 60, day 180</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on mortality during hospitalization and up to 180 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Arterial ECMO duration</measure>
    <time_frame>up to 180 days (from date of randomization until ECMO weaning)</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on VA-ECMO weaning time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>day 30, Day 60, Day 180</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on adverse cardiovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac transplant</measure>
    <time_frame>day 30, Day 60, Day 180</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on adverse cardiovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>escalation to Left Ventricular Assist Device</measure>
    <time_frame>day 30, Day 60, Day180</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on adverse cardiovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>Day 30, Day 60, Day 180</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on adverse cardiovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulated amount of administered fluids</measure>
    <time_frame>up to 180 days (from date of randomization until ECMO weaning)</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on necessity of fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulated amount of vasopressors use</measure>
    <time_frame>up to 180 days (from date of randomization until ECMO weaning)</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on necessity of vasopressor (norepinephrine, epinephrine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate</measure>
    <time_frame>up to 180 days (from date of randomization until ECMO weaning)</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on lactate clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>from baseline until Day 30</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on duration of organ failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>baseline, day 30, day 60 and day 180</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on mechanical ventilation support use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy</measure>
    <time_frame>from baseline until day 30, day 60, day 180</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on renal replacement therapy use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit stay</measure>
    <time_frame>Day 30; Day 60; Day 180</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on duration of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization stay</measure>
    <time_frame>Day 30; Day 60; Day 180</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on duration of total hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding complications</measure>
    <time_frame>Hour 48, Day 7</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on the risk of bleeding under ECMO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>packed red blood cells transfused</measure>
    <time_frame>Hour 48, Day 7</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on the risk of bleeding under ECMO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>Hour 48, Day 7, Day 30, Day 60, day 180</time_frame>
    <description>Evaluation of the impact of moderate hypothermia on risk of sepsis (pulmonary, blood, venous lines, cannulaes)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">334</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>Moderate hypothermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate hypothermia :Patients with cardiogenic shock treated with arteriovenous ECMO to a strategy of moderate hypothermia during 24 hours (Temperature at 33°C≤ T°C ≤34°C) associated with usual care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normothermia</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Normothermia: Patients with cardiogenic shock treated with arteriovenous ECMO to a strategy of normothermia (36°C≤ T°C ≤37°C) associated with usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>moderate hypothermia</intervention_name>
    <description>moderate hypothermia will be induced using the heat controller of the VA-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 24 hours ± 1h followed by a progressive reheating (0.2±0.1°C/h) to reach 37 °C. Temperature at 37°C ± 0.3°C will be maintained during 48 hours ± 4h after having reached 37 °C.</description>
    <arm_group_label>Moderate hypothermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Intubated patients with cardiogenic shock treated with VA-ECMO

          -  Patient affiliated to social security plan

        Exclusion Criteria:

          -  VA-ECMO after cardiac surgery for heart transplantation or lung transplantation or
             left or biventricular assist device implantation

          -  VA-ECMO for acute poisoning with cardio-toxic drugs

          -  Pregnancy

          -  Uncontrolled bleeding (bleeding despite medical intervention (surgery or drugs))

          -  Implantation of VA ECMO under cardiac massage with a duration of cardiac massage
             &gt;45minutes

          -  Out of hospital refractory cardiac arrest

          -  Cerebral deficit with fixed dilated pupils

          -  Participation in another interventional research involving therapeutic modifications

          -  Patient moribund on the day of randomization

          -  Irreversible neurological pathology

          -  Minor patients

          -  Patients under tutelage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno LEVY, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain COMBES, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>APHP-Pitié Salpêtrière</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabrice VANHUYSE, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas GIRERD, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick ROSSIGNOL, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens - Picardie -Site sud</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Annecy Centre Hospitalier</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Besançon Hôpital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Groupe Hospitalier SaintAndré</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand -Hopital G. Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon - Hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM-Hôpital, de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes/ Hôpital Nord Laennec</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP- Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP- la Pitié Sapêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aphp-Hegp</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP-Pitié</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg/ NHC</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse Hôpital - Pierre Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venous-Arterial ExtraCorporeal Membrane Oxygenation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

